GLP1 poly-agonist peptides
GLP1 poly-agonist peptides[1] are a class of drugs that activate multiple peptide hormone receptors including the glucagon-like peptide-1 (GLP-1) receptor. These drugs are developed for the same indications as GLP-1 receptor agonists—especially obesity, type 2 diabetes, and non-alcoholic fatty liver disease. They are expected to provide superior efficacy with fewer adverse effects compared to GLP-1 mono-agonists, which are dose-limited by gastrointestinal disturbances.[2] The effectiveness of multi-receptor agonists could possibly equal or exceed that of bariatric surgery. The first such drug to receive approval is tirzepatide, a dual agonist of GLP-1 and GIP receptors.[1]
GLP-1 and GIP receptor dual agonists
[edit]Tirzepatide, a dual agonist of GLP-1 and GIP receptors, is approved for type 2 diabetes and obesity. With an average 20 percent weight loss at a high dosage, it appears to be more effective than GLP-1 mono agonists although there have been no head to head trials as of 2023.[1][3]
GLP-1 and glucagon receptor dual agonists
[edit]Glucagon is a hormone that generally opposes the action of insulin.[4] It increases blood glucose by stimulating the production of glucose in the liver via glycogenolysis (breakdown of glycogen) and gluconeogenesis (production of glucose from non-carbohydrate sources).[5] Glucagon also increases the breakdown of lipids and amino acids and the production of ketones.[6][7] Unlike currently approved weight loss drugs, glucagon receptor agonists increase energy expenditure.[8] Combination GLP-1/glucagon receptor agonists provide the thermogenic benefits of glucagon activation while almost eliminating hyperglycemia induced by glucagon receptor activation. Several such drugs have reached human trials for obesity, diabetes, and non-alcoholic fatty liver disease but adverse effects have hampered development. The most advanced of these drugs is mazdutide which is in a phase III trial as of 2023.[5]
GLP-1, GIP, and glucagon receptor triple agonists
[edit]Following the discovery of GLP-1/GIP and GLP-1/glucagon dual agonists, it was hoped that a triple agonist would provide additive or synergistic metabolic benefits.[9] A clinical trial of the triple agonist retatrutide found an average −24.2 percent weight reduction in the highest dosage group after 24 weeks.[10]
Conjugates
[edit]Attaching other hormones such as estrogen, thyroid hormone (T3), and dexamethasone to GLP-1 or glucagon restrict the activity of the attached hormone to cells that express GLP-1 or glucagon.[9]
GLP-1 and amylin receptor agonist conjugates have also been tested in preclinical trials.[9]
GLP-1 and neuropeptide Y multi-agonists
[edit]In 2023, researchers disclosed the discovery of multiple peptides that activated the GLP-1 receptor, neuropeptide Y receptor Y1, and neuropeptide Y receptor Y2. Since neuropeptide Y receptors were a previous anti-obesity target, it is hoped that the combination might be more efficacious than GLP-1 receptor agonists.[11]
See also
[edit]References
[edit]- ^ a b c Statham, Laura; Pelling, Melina; Hanson, Petra; Kyrou, Ioannis; Randeva, Harpal; Barber, Thomas M (4 May 2023). "Designer GLP1 poly-agonist peptides in the management of diabesity" (PDF). Expert Review of Endocrinology & Metabolism. 18 (3): 231–240. doi:10.1080/17446651.2023.2204976. PMID 37089108.
- ^ Capozzi, Megan E; DiMarchi, Richard D; Tschöp, Matthias H; Finan, Brian; Campbell, Jonathan E (2018). "Targeting the Incretin/Glucagon System With Triagonists to Treat Diabetes". Endocrine Reviews. 39 (5): 719–738. doi:10.1210/er.2018-00117. PMC 7263842. PMID 29905825.
- ^ "FDA Approves Diabetes Drug Tirzepatide for Chronic Weight Management". AJMC. 8 November 2023. Retrieved 16 November 2023.
- ^ Finan, Brian; Capozzi, Megan E.; Campbell, Jonathan E. (1 April 2020). "Repositioning Glucagon Action in the Physiology and Pharmacology of Diabetes". Diabetes. 69 (4): 532–541. doi:10.2337/dbi19-0004. PMC 7085250. PMID 31178432.
- ^ a b Novikoff, Aaron; Müller, Timo D. (2023). "The molecular pharmacology of glucagon agonists in diabetes and obesity". Peptides. 165: 171003. doi:10.1016/j.peptides.2023.171003. ISSN 0196-9781. PMC 10265134. PMID 36997003.
- ^ Patil, Mohan; Deshmukh, Nitin J.; Patel, Mahesh; Sangle, Ganesh V. (May 2020). "Glucagon-based therapy: Past, present and future". Peptides. 127: 170296. doi:10.1016/j.peptides.2020.170296. PMID 32147318. S2CID 212408895.
- ^ Capozzi, Megan E.; D’Alessio, David A.; Campbell, Jonathan E. (2022). "The past, present and future physiology and pharmacology of glucagon". Cell Metabolism. 34 (11): 1654–1674. doi:10.1016/j.cmet.2022.10.001. ISSN 1550-4131. PMC 9641554. PMID 36323234.
- ^ Sánchez-Garrido, Miguel A.; Brandt, Sara J.; Clemmensen, Christoffer; Müller, Timo D.; DiMarchi, Richard D.; Tschöp, Matthias H. (2017). "GLP-1/glucagon receptor co-agonism for treatment of obesity". Diabetologia. 60 (10): 1851–1861. doi:10.1007/s00125-017-4354-8. PMC 6448809. PMID 28733905.
- ^ a b c Brandt, S. J.; Müller, T. D.; DiMarchi, R. D.; Tschöp, M. H.; Stemmer, K. (December 2018). "Peptide‐based multi‐agonists: a new paradigm in metabolic pharmacology". Journal of Internal Medicine. 284 (6): 581–602. doi:10.1111/joim.12837. PMID 30230640.
- ^ Jastreboff, Ania M.; Kaplan, Lee M.; Frías, Juan P.; Wu, Qiwei; Du, Yu; Gurbuz, Sirel; Coskun, Tamer; Haupt, Axel; Milicevic, Zvonko; Hartman, Mark L. (2023). "Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial". New England Journal of Medicine. 389 (6): 514–526. doi:10.1056/NEJMoa2301972. PMID 37366315. S2CID 259260926.
- ^ Chichura, Kylie S.; Elfers, Clinton T.; Salameh, Therese S.; Kamat, Varun; Chepurny, Oleg G.; McGivney, Aelish; Milliken, Brandon T.; Holz, George G.; Applebey, Sarah V.; Hayes, Matthew R.; Sweet, Ian R.; Roth, Christian L.; Doyle, Robert P. (12 June 2023). "A peptide triple agonist of GLP-1, neuropeptide Y1, and neuropeptide Y2 receptors promotes glycemic control and weight loss". Scientific Reports. 13 (1): 9554. Bibcode:2023NatSR..13.9554C. doi:10.1038/s41598-023-36178-1. ISSN 2045-2322. PMC 10261008. PMID 37308546.